Compound class:
Synthetic organic
Comment: Compound 8h is reported as an inhibitor of wild type BCR-Abl and its gatekeeper mutant T315I [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Although compound 8h is reported as a BCR-Abl inhibitor it also has IC50s <1nM for the EPHA2 and RET kinases [1]. IC50s of 1-10nM are reported for many other kinases such as CDK2, EPHA3, EPHA7, FGFR1 and -2, VEGFRs 1-3, FMS, FLT3, LYN, PDGFRα and -β, TEC and Src [1]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
Selectivity at catalytic receptors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|